Jane Street
NWBO

Jane Street’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Jane Street’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-23,611
Closed -$13K – 5027
2016
Q3 		$13K Buy
+23,611
New +$10.8K ﹤0.01% 3918
2015
Q2 		– Sell
-12,524
Closed -$92K – 4438
2015
Q1 		$92K Buy
+12,524
New +$84.3K ﹤0.01% 3014
2014
Q3 		– Sell
-34,350
Closed -$231K – 3587
2014
Q2 		$231K Sell
34,350
-150,079
-81% -$955K ﹤0.01% 2079
2014
Q1 		$1.34M Buy
184,429
+110,899
+151% +$657K 0.01% 762
2013
Q4 		$277K Buy
+73,530
New +$285K ﹤0.01% 1725
2013
Q3 		– Sell
-26,145
Closed -$87K – 3609
2013
Q2 		$87K Buy
+26,145
New +$94.8K ﹤0.01% 2465

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CDH
Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
MBT
Montecito Bank & Trust Santa Barbara, California $668M AUM 24.84% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BW
Biegel & Waller Columbia, Maryland $179M AUM 1.6% 1-Year Est. Return
MPI
Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return

Jane Street's NWBO Position: Q4 2016 in Review

Jane Street sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2016, closing a stake of 23,611 shares — an estimated $13K sold.

Jane Street first reported a position in NWBO in Q2 2013 and held it in 6 quarters. The position peaked at $1.34M in Q1 2014. 8 funds tracked by Wall St. Rank hold NWBO as of Q4 2016.

  • Jane Street reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2016 after selling out during the quarter.
  • Jane Street sold 23,611 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2016, an estimated $13K.
  • Jane Street first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2013 and held it in 6 quarters.
  • Jane Street's Northwest Biotherapeutics, Inc. Common stock position peaked at $1.34M in Q1 2014.
  • 8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2016.

Based on Jane Street's 13F filing for Q4 2016, filed 15 Feb 2017.